P-MUC1C-ALLO1
Solid Tumors (Breast, Ovarian, Pancreatic, etc.)
Phase 1Active (Transferred to Roche)
Key Facts
Indication
Solid Tumors (Breast, Ovarian, Pancreatic, etc.)
Phase
Phase 1
Status
Active (Transferred to Roche)
Company
About Poseida Therapeutics
Poseida Therapeutics was a San Diego-based biotech focused on developing next-generation cell and gene therapies with its non-viral engineering platforms. Its core strategy centered on overcoming the limitations of viral vectors to create CAR-T products with a high proportion of stem cell memory T cells for enhanced persistence and potency. The company advanced a pipeline of autologous and allogeneic CAR-T candidates targeting hematological malignancies and solid tumors. Its significant technological achievements culminated in its acquisition by Roche in 2024, validating its platform and providing a path for accelerated development.
View full company profile